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The ongoing Ebola outbreak poses an alarming risk to the countries of West Africa and beyond. On August 8, 2014,
the World Health Organization (WHO) declared the cross-country Ebola outbreak a Public Emergency of International
Concern. China has had no confirmed cases of Ebola. In this paper, virologic characteristics, pathogenesis, clinical
manifestations, laboratory examination and prophylactic vaccines and therapeutic drugs of Ebola are summarized.
Importantly, active responses and actions from China are introduced. Moreover, the key issues in the future prevention
and control of Ebola were also addressed.
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Ebola virus disease (EVD) is an acute severe illness which
is often fatal if untreated. The origin of the virus is un-
known, but fruit bats (Pteropodidae) and other non-
human primates are considered as potential host of the
Ebola virus (EBOV) [1,2]. EVD, initially discovered in
1976, was named after the Ebola River in Yambuku,
Democratic Republic of Congo, where the first series of
cases occurred. Previous EVD outbreaks were localized
to remote areas in Central Africa, while the most recent
epidemic in West Africa spread to rural and even urban
areas. The EVD fatality rate reported in past outbreaks
ranged from 25% to 90% [3].
The current Ebola outbreak in West Africa (first case
reported on March 23, 2014) is the most serious and ex-
tensive outbreak since the EBOV was discovered. The
number of incident cases and deaths was greater than
other outbreaks in history. The most severely affected
countries, including Guinea, Sierra Leone and Liberia
have just survived from long periods of conflict and in-
stability, and are equipped with fragile health systems
which are short-handed in human and infrastructural re-
sources. As of November 23, 2014, 15,935 Ebola cases
and 5,689 deaths have been reported in eight affected
countries, including Guinea, Liberia, Mali, Sierra Leone,* Correspondence: lijin20130605@163.com; junsheng_ji302@163.com
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There are a total of 592 health-care workers (HCWs) in-
fected with EVD as of November 23 and 340 of them have
died [4].
Notably, evidence from the current Ebola epidemic and
previous outbreaks strongly suggest the following epidemio-
logical features of EBOV: non-airborne (not transmitted
through a cough or sneeze) with a primary transmission
route of direct contact with contaminated fluids, broken
skin or mucous membranes. However, questions still re-
main concerning vomit and diarrheal fluids. Interestingly,
the family of America’s first diagnosed Ebola patient did
not acquire infection despite their common residence in
which the patient had already been vomiting and having
diarrhea. Due to lack of sufficient research, hard scientific
evidence is still rare, so current assertions on the route
of transmission are primarily based on observations by
epidemiologists [5].Main text
Virologic characteristics of EBOV
EBOV belongs to the family Filoviridae, a taxonomic
group of enveloped, non-segmented, negative-strand RNA
viruses with an 18.9 kb RNA genome. The Filoviridae
virus family includes three genera: Cueva virus, Marburg
virus, and EBOV. Ebola virions are uniform, with a diam-
eter of 70–90 nm and a length of 300–1500 nm. The en-
velope, putatively derived from the host cell membrane,
binds a 45–60 nm diameter nucleocapsid [6]. EBOV ishis is an Open Access article distributed under the terms of the Creative
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Zaïre, Côte d’Ivoire and Reston. The first three species
of EBOV have been linked to outbreaks in Africa, whereas
the Côte d’Ivoire and Reston subspecies have not been as-
sociated with any Ebola hemorrhagic fever (EHF) human
outbreaks to date. The virus responsible for the 2014 West
African outbreak belongs to the Zaïre species. The
genome of Zaïre EBOV encodes seven polyproteins and
one non-structural protein, including the glycoprotein
(GP), nucleoprotein (NP), RNA-dependent RNA poly-
merase (L), virion protein (VP) 24, VP30, VP35, VP40, and
secreted glycoprotein (sGP) [7,8].
EBOV genome is relatively simple, but the molecular
basis for EBOV interaction with host cells remains un-
clear. The mechanism by which EBOV infects cells might
rely on two types of glycoprotein, in either a secreted or
transmembrane form. Yang et al. [9] observed that sGP
interacted with neutrophils through CD16b to inhibit
early neutrophil activation, whereas the transmembrane
glycoprotein interacted with endothelial cells likely con-
tributing to the hemorrhagic symptoms of this disease.
Additionally, the VP40 matrix protein and VP24 of EBOV
might play a role with the formation of the surrounding
envelope, virus assembly and budding [10,11], however,
VP30 and VP35 might involve the transcription and
replication of Ebola. NP, the primary structural protein,
was associated with filovirus nucleocapsids [12]. Fortu-
nately, to date, no evidence has shown that mutations
could significantly alter the virulence, spread and patho-
genicity of EBOV.
Pathogenesis of EVD
The pathogenesis of EVD remains unclear. The incuba-
tion period of EBOV may depend on the infection route
(e.g., 6 days for injection versus 10 days for contact).
Migration of EBOV originates from the primary site of
infection to regional lymph nodes, followed by vascular
spread through the bloodstream to dendritic cells and
macrophages within the liver, spleen, thymus, and other
lymphoid tissues [13].
After infecting the host through mucosal membranes,
broken skin, or through parental transmission, circulating
EBOV can infect several cell types including monocytes,
macrophages, dendritic cells, endothelial cells, hepatocytes
and some epithelial cells. Although lymphocytes are
known to be resistant against EBOV, they undergo apop-
tosis leading to a decrease in lymphocyte counts. An infer-
ence can be drawn that the cells above might express
entry receptors of EBOV. Replication of filoviruses in
widespread macrophages and dendritic cells, namely
‘sentinel’ cells, results in their necrosis and the release of
abundant new viral particles into extracellular fluid [14].
Meanwhile, hepatocytes are destroyed and necrosis oc-
curs, leading to dysregulation of clotting factors and evencoagulopathy. Adrenocortical necrosis can also be ob-
served, causing hypotension and impaired steroid syn-
thesis. In addition to causing extensive tissue damage,
EBOV also triggers macrophages, monocytes and other
cells to release a cocktail of cytokines, chemokines, and
a series of pro-inflammatory cytokines, such as tumor
necrosis factor-alpha, interleukin (IL)-1beta, IL-6, macro-
phage chemotactic protein (MCP)-1, and nitric oxide,
which not only destroy the vascular endothelium but also
activate the coagulation cascade [15,16].
Interestingly, EBOV impairs the antigen-specific immune
responses in both direct and indirect ways [17]. Filoviruses
cause a severe and frequently fatal illness, partially, due
to damage of dendritic cell function and promotion of
lymphocyte apoptosis. As to the function of dendritic
cells, they bear the primary responsibility to start the
adaptive immune response and are a major site for rep-
lication of filoviruses. According to several in vitro in-
vestigation studies, infected dendritic cells fail to present
antigens to naive lymphocytes attributing to the lack of
mature cell development. These results suggest an under-
lying mechanism as to why patients dying from EVD may
not develop antibodies to the virus [18,19]. Moreover, at-
trition of lymphocytes is another phenomenon observed
in lethal EBOV infection. Although lymphocytes are not
directly infected by EBOV, the overall systemic infection
induces massive bystander apoptosis [20,21].
EBOV infection will result in multi-organ failure and
shock, which appears to be caused by clotting disorders
and vascular leakage. There are two stimulus factors, coagu-
lation defects and virus-infected macrophages synthesizing
cell-surface tissue factor (TF), which happen simultaneously
and may contribute to the rapid progress and critical sever-
ity of the coagulopathy involved with EBOV infection. The
former events appear to be triggered indirectly by the host
inflammatory response, while the latter is activated the
extrinsic coagulation pathway. Moreover, pro-inflammatory
cytokines also induce macrophages to produce TF. In
addition, other factors such as activated protein C and
platelets may also be involved with the coagulation de-
fects in EVD. A study by Hotchkiss RS and colleagues
[22] showed that in EBOV-infected macaques, levels of
activated protein C begin to decrease on day two post
infection, while platelet counts decrease three or four
days following infection, indicating that activated plate-
lets are adhering to endothelial cells. Throughout EBV
development, involvement of organ dysfunction such as
hepatic injury will further cause a decline in plasma
levels of certain coagulation factors.
Clinical manifestations of EVD
The clinical symptoms of EVD are characterized with
acuteness, severity and multi-organ involvement. The
WHO’s definition of the incubation period or the time
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toms, is 2 to 21 days [23]. The clinical presentations of
EVD begins with an abrupt onset of fever and are char-
acterized, initially, by a nonspecific flu-like illness such
as fever, headache, malaise, myalgia, sore throat and gastro-
intestinal symptoms such as nausea vomiting, diarrhea and
abdominal pain. Electrolyte derangements are mostly sec-
ondary to the diarrhea and vomiting. Severe hypokalemia
along with moderate degrees of hypocalcaemia and hypo-
magnesaemia have been reported. In addition, capillary
leakage combined with intravenous volume resuscita-
tion commonly result in significant third spacing and
peripheral edema. Although cough can occur, it is not a
primary feature of this illness. Hiccups and dysphagia
are often present, with severe associated discomfort.
Hemorrhagic manifestations occurred in less than 10%
of clinical cases, but these cases were relatively severe
with poor outcomes. Primary causes of death are typic-
ally hypovolemic shock due to oro-gastric losses and
third spacing (not hemorrhagic) related to severe elec-
trolyte abnormalities. Renal failure is frequent in the
late phase of severe disease. Prompt and accurate diag-
nosis of Ebola cases is essential to curb the Ebola out-
break. Differential diagnosis of EVD should take into
account other acute Filovirus diseases as well as infec-
tious diseases with similar clinical manifestations, such
as malaria and typhoid fever.
Laboratory examination of Ebola virus infection
Laboratory screening and diagnosis technologies of EBOV
are limited, but are generally reliable. Early leukopenia,
lymphopenia, atypical lymphocytosis and elevated AST
and ALP are the main laboratory abnormalities indicative
of EVD. Prothrombin and partial thromboplastin times
are prolonged, and the detection of fibrin split products
indicates disseminated intravascular coagulation. No sin-
gle laboratory test will yield a definitive diagnosis of EBOV
infection. The definitive diagnosis of EBOV infection can
be made by laboratory tests including antibody-capture
enzyme-linked immunosorbent assay (ELISA), antigen-
capture detection tests, serum neutralization test, reverse
transcriptase polymerase chain reaction assay (RT-PCR),
electron microscopy, and virus isolation by cell culture (if
necessary) [24]. Among these methods, RT-PCR is one of
the most rapid and powerful tools for diagnosis of filovirus
infection.
All laboratory testing should be performed in adherence
with appropriate laboratory safety guidelines. Maximum
biological containment conditions, such as biosafety level
4 laboratories (BSL-4), should be utilized for laboratory
testing, regardless of whether the samples are inactivated.
Any samples from patients, such as acute sera, post-
mortem tissue specimens, and materials collected dur-
ing ecological investigations are of extreme biohazardrisk. Therefore, maximum feasible precautions such as
mask respirators, gloves and gowns are required when
collecting any samples that may contain filoviruses. In
September 2014, the WHO provided interim infection
control recommendations addressing patient care, waste
management, disposal of human remains, and other mea-
sures [25].
Chinese scientists have developed several detection kits
for EBOV in August, including a fluorescence RT-PCR
nucleic acid detection kit, colloidal gold immune chro-
matography antigen detection kit and ELISA antigen
detection kit, which have been used in the laboratory
examination of Ebola.Prophylactic vaccines and therapeutic drugs against
EBOV
During the past several years, progress on development
of potential vaccines against EBOV has been made, but
the progress and development of antiviral drugs and other
post-exposure interventions has been much slower. Re-
trieving the Cortellis database of Thomson Reuters com-
bined with knowledge of EBOV to analyze current R&D
of medicines and vaccines for EVD, the study findings
show that there are mainly five important categories:
vaccines, neutralizing antibodies, small-molecule anti-
Ebola drugs, RNA interference (RNAi) drugs and nucleo-
tide drugs. In each category, there are promising products
under development that are worthy of attention.
Due to the lack of effective drugs available for EVD,
the supportive treatments for complications such as
septic shock, hematologic abnormalities, hypovolemia,
refractory shock, hypoxia, electrolyte abnormalities,
hemorrhage, multi-organ failure, and DIC should be
emphasized. Severely ill patients require intensive sup-
portive care [26]. For EVD patients, oral anti-emetics,
anti-diarrheal therapy and adequate rehydration are
very essential. In addition, infection prevention and con-
trol measures are a critical part of clinical management
[27,28]. Although robust data are still lacking, clinical ex-
perience from EVD patients treated during the current
outbreak suggests that the mortality rate associated with
EVD can be significantly reduced through the provision of
supportive care, and in particular critical care [29].
In the 2014 Ebola epidemic, after receiving an experi-
mental drug called ZMapp, two American aid workers
who fell sick with EVD in Liberia survived successfully.
ZMapp was developed by San Diego-based private bio-
tech firm Mapp Biopharmaceutical. A previous study
suggests that ZMapp supplies the best option for experi-
mental therapeutics used for treating EBOV-infected pa-
tients [30]. Potential treatments, including monoclonal
antibody administration and small inhibitory RNA mole-
cules, are still under scientific investigation.
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tially effective vaccines have entered the stage of human
safety testing: cAd3-ZEBOV and rVSV-ZEBOV. The first
vaccine is composed of a chimpanzee-derived adenovirus
vector with an EBOV gene inserted. This vaccine is be-
ing jointly developed by GlaxoSmithKline with the US
National Institute of Allergy and Infectious Diseases.
An attenuated strain of Vesicular stomatitis virus (VSV), a
pathogen normally found in livestock, is included in the
second vaccine and one of the VSV genes is replaced by
an EBOV gene. The second vaccine is being developed
by the Public Health Agency of Canada in Winnipeg,
while the license for its commercialization is held by
NewLink Genetics Company, an American company in
Ames, Iowa [31].
Positive anti-Ebola response and action from China
Since the aftermath of the Severe Acute Respiratory
Syndrome outbreak in 2003, China has developed a
relatively strong system and accumulated precious ex-
perience for the prevention and control of emerging in-
fectious diseases, which has been proven crucial and
effective in controlling the H5N1 avian influenza epidemic
in 2005, H1N1 influenza outbreak in 2009 and other pub-
lic health emergencies. Facing the severe Ebola epidemic
in West Africa, China has made positive and active ac-
tions, providing aids in the prevention and control of
Ebola.
As of November 21, 2014, China successively provided
four rounds of emergency aids with a total value of 750
million yuan to Ebola-affected countries. The medical
staff from China has reached 400 man-times. In Sierra
Leone, sample tests conducted by the mobile laboratory,
supported by China, accounted for over 20% of total tests
with accuracy up to 100%.Two-thirds of the international
anti-Ebola material assistance received by Guinea came
from China. Additionally, almost all the anti-Ebola mate-
rials within the ten countries surrounding the epidemic
areas were offered by China. Approximately 1,000 people-
composed of Chinese medical technicians and public
health experts will be sent to the front-lines to battle
against Ebola in the months ahead. An anti-Ebola training
plan involving over 10,000 medical workers and commu-
nity staff will soon be initiated by China.
China has implemented a serious of effective prevention
and control strategies. For example, China has controlled
the following entry gateways that Ebola has possibly
invaded: 1) Entry gateway. China has instituted strict
controls at airports, customs, and exit and entry ports,
strengthened the quarantine work of each port and
health monitoring of the passengers from Ebola epidemic
areas. 2) Quarantine. Isolation and control of potential in-
fection sources is the key measure to prevent and control
Ebola. People returning from West African countries mustremain in strict quarantine and people with positive or
suspicious contact histories must remain in isolation. 3)
National emergency. China has set up a strong infectious
disease control and prevention system on the basis of
knowledge acquired during the SARS outbreak following
several public health urgencies. 4) Medical care. Medical
staff is informed of the disease nature and an informa-
tion bulletin is provided in a timely manner and strictly
adhered to by the recommended infection control
guidelines. 5) First aid. Once the Ebola virus infection
appears, patients should be given symptomatic and
supportive treatment. 6) Personal protection. Scientific
understanding of the transmission route of Ebola can
effectively control the spread of Ebola. 7) Etiquette cus-
tom. In the face of the highly contagious and lethal EBOV,
we should change the handshake etiquette to avoid
shaking hands and hugging with others. 8) Environmental
sanitation. Maintaining proper sanitation is the key to pre-
vent and control infectious diseases. Only when all these
strategies have been implemented, will the transmission of
disease in our country lessen.
In addition, Traditional Chinese Medicine has a place
in preventing and treating emerging infectious diseases. In
2009 H1N1 epidemic, the Chinese medicine Maxingshigan-
yinqiaosan formula showed the similar efficacy with
oseltamivir in treating human H1N1. Traditional Chinese
herbal therapy may be considered for a treatment option
for Ebola [32].
Conclusions
By analyzing detailed data from 3,343 confirmed and 667
probable Ebola cases collected in Guinea, Liberia, Nigeria,
and Sierra Leone from March 23, 2014 to September 14,
2014, a WHO Ebola Response Team study shows that
the basic reproduction number (R0), estimated current
reproduction numbers (R) and corresponding doubling
times for Guinea were 1.71, 1.81 and 15.7 days, respect-
ively. Those values for Liberia were 1.83, 1.51 and 23.6 days,
while for Sierra Leone they were 2.02, 1.38 and 30.2 days,
respectively [33]. Notably, a susceptible-exposed-infectious-
recovered model predicted the R0 of EVD in China is 1.53-
3.54, which means a total of 6–194 imported cases [34].
The data above indicate that if strengthened control mea-
sures were not implemented, EVD cases and deaths associ-
ated with the disease would continue to grow in the near
future in several currently affected areas and could even
spread to surrounding countries.
Because the Ebola epidemic might last for another 6–9
months [35], developed countries and international aid
groups should strengthen the support not only by send-
ing more medical staff but also by helping these coun-
tries to establish suitable public health prevention and
control systems. Positive anti-Ebola response and action
plans from China have been proven effective.
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drugs are the main focus in next step. These top inter-
national pharmaceutical companies should put the drive
for the profit aside and join the global intelligence to
develop protective vaccines and effective drugs. As dis-
cussed above, the epidemiological features, pathogenesis,
prognosis and outcomes associated with Ebola remain un-
clear. Therefore, more research should be conducted on
these aspects to provide evidence for the prevention and
control of Ebola. Genetic mutation of EBOV should be
closely monitored, especially the effect of mutations on
the virulence and transmission routes. Hopefully, under
the global effort, the challenge brought by Ebola outbreak
will be conquered in the near future.
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